Martin Javier San net worth and biography

Martin San Biography and Net Worth

Insider of Athira Pharma

Javier joined LeonaBio as Chief Medical Officer in April 2024. He has more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategy for multiple drugs across large and rare diseases with significant unmet medical need. Throughout his career, Javier has guided therapies from proof-of-concept through regulatory approval, with special emphasis on aligning late-stage development efforts with viable commercialization paths.

Prior to joining LeonaBio, Javier served as Chief Medical Officer of Arrowhead Pharmaceuticals, where he guided development teams to advance that company’s RNAi-based therapeutics in the metabolic and liver disease area. Prior to Arrowhead, he served as Senior Vice President and Head of Global Clinical Development at Ultragenyx Pharmaceutical, where he led the development of Crysvita^® (burosumab-twza), the first drug approved to treat the rare, inherited disease of x-linked hypophosphatemia. Before that, he served as Senior Vice President of Clinical Development at Alder Biopharmaceuticals.

Javier received his medical degree from the University of Buenos Aires Medical School and completed his residence in internal medicine at CEMIC University of Buenos Aires.

What is Martin Javier San's net worth?: The estimated net worth of Martin Javier San is at least $93.65 thousand as of March 4th, 2026. San owns 15,887 shares of Athira Pharma stock worth more than $93,654 as of September 23rd. This net worth approximation does not reflect any other assets that San may own. Learn More about Martin Javier San's net worth.
How do I contact Martin Javier San?: The corporate mailing address for San and other Athira Pharma executives is 18706 North Creek Parkway, Suite 104, Bothell, WA, 98011. Athira Pharma can also be reached via phone at 425-620-8501 and via email at [email protected]. Learn More on Martin Javier San's contact information.
Has Martin Javier San been buying or selling shares of Athira Pharma?: Martin Javier San has not been actively trading shares of Athira Pharma within the last three months. Most recently, Martin Javier San sold 1,720 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a transaction totalling $9,236.40. Following the completion of the sale, the insider now directly owns 15,887 shares of the company's stock, valued at $85,313.19. Learn More on Martin Javier San's trading history.
Who are Athira Pharma's active insiders?: Athira Pharma's insider roster includes Mark Litton (CEO), Robert Renninger (CFO), Martin San (Insider), and Mark Worthington (General Counsel). Learn More on Athira Pharma's active insiders.
Are insiders buying or selling shares of Athira Pharma?: In the last twelve months, insiders at the sold shares 8 times. They sold a total of 14,513 shares worth more than $86,093.34. The most recent insider tranaction occured on March, 4th when insider Martin Javier San sold 1,720 shares worth more than $9,236.40. Insiders at Athira Pharma own 25.7% of the company. Learn More about insider trades at Athira Pharma.
Information on this page was last updated on 3/4/2026.

Martin Javier San Insider Trading History at Athira Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2026	Sell	1,720	$5.37	$9,236.40	15,887
1/2/2026	Sell	1,644	$6.88	$11,310.72	10,189
7/1/2025	Sell	1,084	$2.90	$3,143.60	7,166
1/2/2025	Sell	1,082	$5.60	$6,059.20	3,584

Martin Javier San Buying and Selling Activity at Athira Pharma

Athira Pharma Company Overview

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Today's Range

Now: $5.89

$5.69

$6.35

50 Day Range

MA: $7.50

$6.05

$8.53

2 Week Range

Now: $5.89

$3.60

$14.21

Volume

21,384 shs

Average Volume

52,104 shs

Market Capitalization

$55.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05